Please assess the completion status of the following clinical trial:

Trial Title: EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Male or female ≥ 18 years of age;~* Hospitalized for a recent ACS;~* LDL-C levels defined as follows:~* LDL-C ≥70 mg/dL (≥1.8 mmol/L) or non-HDL-C ≥100 mg/dL (≥2.6 mmol/) in patients who have been receiving stable treatment with high-intensity statin within ≥ 4 weeks prior to enrollment (i.e. continuous treatment that has not changed with regard to statin intensity over the past 4 weeks) or, LDL-C ≥90 mg/dL (≥2.3 mmol/L) or non-HDL-C ≥120 mg/dL (≥3.1 mmol/) in patients who have been receiving stable treatment with low- or moderate-intensity statin within ≥ 4 weeks prior to enrollment (i.e. continuous treatment that has not changed with regard to statin intensity over the past 4 weeks), or LDL-C ≥125 mg/dL (≥3.2 mmol/L) or non-HDL-C ≥155 mg/dL (≥4.0 mmol/) in patients who are statin-naïve or have not been on a stable (unchanged) statin regimen for at least 4 weeks prior to enrollment;~* Ability to understand the requirements of the study and to provide informed consent.~Exclusion Criteria:~* Unstable clinical status (hemodynamic or electrical instability;~* Uncontrolled cardiac arrhythmia, defined as recurrent and symptomatic ventricular tachycardia or atrial fibrillation with rapid ventricular response not controlled by medications in the past 3 months prior to screening;~* Severe renal dysfunction, defined by estimated glomerular filtration rate \<30 ml/min/1.73m2;~* Active liver disease or hepatic dysfunction, either reported in patient medical record or defined by asparate aminotransferase (AST) or alanine aminotransferase (ALT) levels \> 3x the upper limit of normal;~* Reported intolerance to atorvastatin (any dose) OR statin intolerance;~* Known allergy to contrast medium, heparin, aspirin, ticagrelor or prasugrel;~* Known sensitivity to any substances to be administered;~* Patients who previously received evolocumab or other PCSK9 inhibitor;~* Patient who received cholesterol ester transfer protein inhibitors in the past 12 months prior to screening;~* Treatment with systemic steroids or systemic cyclosporine in the past 3 months systemic cyclosporine, systemic steroids (eg. intravenous, intramuscular or per os);~* Known active infection or major hematologic, metabolic, or endocrine dysfunction in the judgment of the Investigator;~* Patients who will not be available for study-required procedures in the judgment of the Investigator;~* Current enrollment in another investigational device or drug study;~* Active malignancy requiring treatment;~* Female of childbearing potential (age \<50 years and last menstruation within the last 12 months), who did not undergo tubal ligation, ovariectomy or hysterectomy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Evolocumab (Type: ACTIVE_COMPARATOR): Evolocumab 140 mg/mL, pre-filled auto-injector pen, 3 injections at day 1 and week 4
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, pre-filled auto-injector pen, 3 injections at day 1 and week 4

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete